ASCENTAGE PHARMA GROUP INTERNATIONAL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.8 HKD | +5.69% |
|
+16.85% | -23.81% |
Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.
Calendar
19/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
19.3
CNY
Average target price
27.24
CNY
Spread / Average Target
+41.18%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.81% | 758M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- 6855 Stock
- News Ascentage Pharma Group International
- Ascentage Pharma CFO Resigns; Shares Fall 5%